date:May 15, 2012
Those results in a small rat study, published in volume 46 ofProcess Biochemistryin 2011, have prompted a human clinical to be commissioned by the same Norwegian organisation.
That hydrolysates-peptides study is due to complete by years end.
ACE inhibitors work by inhibiting the conversion of angiotensin I to the potent vasoconstrictor, angiotensin II, thereby improving blood flow and blood pressure.
Nofima senior scientist and lead author of the study, Asbjrn Gildberg, said the ACE results